The default outcome measure is typically the ASIA (American Spinal Injury Association) Impairment Scale (AIS), which was originally designed as a clinical tool to assess motor and sensory neurologic intactness ( 1). Over the last few years, however, there has arisen an increasing demand among scientists for sensitive outcome measures, specific to SCI, that have been rigorously tested and are appropriate for use in clinical trials.
Paralleling these advances, basic science and clinical research have made great strides in understanding the underlying biological mechanisms altered by SCI, and potential therapies to promote repair and recovery of function are nearly “at our doorstep.” The clinical care and management of spinal cord injury (SCI) has progressed significantly, resulting in an increasing population worldwide of individuals living with SCI.
0 kommentar(er)
